Olmesartan Medoxomil /Amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil /Amlodipine Sandoz, is a angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond monotherapy.

GNH USA supplies Olmesartan Medoxil / Amlodipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil / Amlodipine Sandoz is used in cardiovascular therapy to lower blood pressure through complementary mechanisms. - Hypertension: provides combined angiotensin‑II blockade and calcium‑channel blockade to achieve better blood‑pressure control. - Hypertensive patients with isolated systolic hypertension: adds vasodilatory effect to reduce systolic pressure. - Hypertension uncontrolled on monotherapy: offers an alternative to adding a second antihypertensive agent. - Hypertension with concomitant risk factors (e.g., diabetes, chronic kidney disease): helps reach target pressures recommended by guidelines.

Both components of Olmesartan Medoxil / Amlodipine Sandoz may cause adverse reactions. The profile reflects the known safety data for each drug.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after the first dose. - Flushing: transient warmth or redness of the skin. - Fatigue: general feeling of tiredness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Cardiac arrhythmias: irregular heart rhythm. - Renal impairment: sudden decrease in kidney function. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate creatinine clearance and adjust if necessary. - Hepatic function: check liver enzymes in patients with known liver disease. - Electrolytes: monitor potassium and sodium levels, especially when combined with diuretics. - Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Olmesartan Medoxil / Amlodipine Sandoz can interact with several drug classes; awareness helps prevent clinically relevant events.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma levels, raising hypotension risk. - Lithium: may increase serum lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Diuretics: may potentiate hypotensive response, requiring dose adjustment. - Simvastatin: amlodipine raises simvastatin levels; limit dose to ≤20 mg daily.